Caribou Biosciences Inc’s recently made public that its President and CEO Haurwitz Rachel E. acquired Company’s shares for reported $20400.0 on Mar 14 ’25. In the deal valued at $1.02 per share,20,000 shares were bought. As a result of this transaction, Haurwitz Rachel E. now holds 3,369,395 shares worth roughly $3.17 million.
Then, MCCLUNG BARBARA G sold 3,564 shares, generating $4,811 in total proceeds. Upon selling the shares at $1.35, the Chief Legal Officer now owns 443,502 shares.
Before that, Khan Ruhi Ahmad sold 3,564 shares. Caribou Biosciences Inc shares valued at $4,811 were divested by the Chief Business Officer at a price of $1.35 per share. As a result of the transaction, Khan Ruhi Ahmad now holds 66,936 shares, worth roughly $62919.84.
Evercore ISI downgraded its Caribou Biosciences Inc [CRBU] rating to an In-line from a an Outperform in a research note published on June 03, 2024; the price target was decreased to $3 from $13. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in early November with a ‘”a Neutral”‘ rating. Evercore ISI began covering CRBU with “an Outperform” recommendation on October 31, 2023. Truist started covering the stock on July 11, 2023. It rated CRBU as “a Buy”.
Price Performance Review of CRBU
On Friday, Caribou Biosciences Inc [NASDAQ:CRBU] saw its stock fall -5.02% to $0.94. Over the last five days, the stock has lost -9.70%. Caribou Biosciences Inc shares have fallen nearly -40.94% since the year began. Nevertheless, the stocks have fallen -81.44% over the past one year. While a 52-week high of $5.23 was reached on 01/07/25, a 52-week low of $0.88 was recorded on 03/26/25. SMA at 50 days reached $1.2374, while 200 days put it at $1.7990.
Levels Of Support And Resistance For CRBU Stock
The 24-hour chart illustrates a support level at 0.9095, which if violated will result in even more drops to 0.8800. On the upside, there is a resistance level at 0.9843. A further resistance level may holdings at 1.0296. The Relative Strength Index (RSI) on the 14-day chart is 37.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0548, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.39%. Stochastics %K at 20.92% indicates the stock is a holding.
How much short interest is there in Caribou Biosciences Inc?
A steep rise in short interest was recorded in Caribou Biosciences Inc stocks on 2025-03-14, dropping by 83028.0 shares to a total of 8.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 8.91 million shares. There was a decline of -0.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 18, 2022 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $22 price target.
